UNASSIGNED: Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment. A meticulous analysis of phase 2 and phase 3 data positions retatrutide, CagriSema, survudotide, tirzepatide, semaglutide, and liraglutide in order of effectiveness. While showcasing their efficacy and safety, the review acknowledges the ongoing phase 3 studies, highlighting the need for further exploration of contraindications, dosage, and potential adverse effects to inform personalized treatment decisions.
UNASSIGNED: The ongoing anticipation of long-term benefits, particularly sustained weight loss and cardiovascular outcomes, underscores the significance of future treatment algorithms for addressing the disease of obesity.
■探索机制,功效,和安全概况,这篇综述全面评估了选择性或非选择性结合GLP-1受体的药物治疗肥胖的疗效.对第二阶段和第三阶段数据位置retatrutide进行了细致的分析,CagriSema,survudotide,泰西帕肽,塞马鲁肽,和利拉鲁肽的有效性顺序。在展示其功效和安全性的同时,审查承认正在进行的第三阶段研究,强调需要进一步探索禁忌症,剂量,和潜在的不利影响,以告知个性化的治疗决策。
■对长期利益的持续预期,特别是持续的体重减轻和心血管结局,强调了未来治疗算法对解决肥胖症的重要性。